secwatch.observer — SEC 8-K summary
======================================

Issuer:     Intellia Therapeutics, Inc. (NTLA)
CIK:        0001652130
Form:       8-K
Filed at:   2025-10-27T23:59:59+00:00
Accession:  0001193125-25-250757
Event type: other_material
Sentiment:  negative
Materiality: 0.90
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Intellia pauses dosing in Phase 3 MAGNITUDE trials after Grade 4 liver event in one patient
--------------------------------------------------------------------------------

- Patient dosed on Sept 30, 2025, experienced Grade 4 liver transaminases and increased total bilirubin on Oct 24.
- Patient hospitalized and receiving medical intervention; Intellia consulting experts and regulators.
- Pause affects both MAGNITUDE (ATTR-CM, >650 enrolled) and MAGNITUDE-2 (ATTR-PN, 47 enrolled) trials.
- Over 450 patients estimated to have been dosed with nex-z across both trials to date.
- Conference call scheduled at 8:30 a.m. ET today to discuss the update.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1652130/000119312525250757/0001193125-25-250757-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1652130/000119312525250757/d44351d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-250757

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer